USD 4.72
↓ -0.41 (-7.99%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| CCCC | -8.0 | -22.1 | -25.1 | -19.5 | -22.7 | 162.2 | -88.7 | -81.5 | -81.5 | -81.5 |
| S&P 500 | -0.6 | -0.5 | 2.3 | 7.3 | 12.1 | 32.1 | 27.0 | 90.7 | 191.4 | 33587.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | CCCC |
| name | C4 Therapeutics, Inc. |
| price | 4.72 |
| changes percentage | -7.99 |
| change | -0.41 |
| day low | 4.72 |
| day high | 5.14 |
| year high | 11.88 |
| year low | 1.06 |
| market cap | 333180080 |
| price avg 50 | 5.93 |
| price avg 200 | 6.46 |
| exchange | NASDAQ |
| volume | 958330 |
| avg volume | 984337 |
| open | 5.14 |
| previous close | 5.13 |
| eps | -1.71 |
| pe | -2.76 |
| earnings announcement | 2025-02-20T12:00:00.000+0000 |
| shares outstanding | 70589000 |
| timestamp | 2024-11-14 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001662579 | |||
| revenue | 20756000 | 31096000 | -33.25 |
| gross profit | -96950000 | 23524000 | -512.13 |
| gross profit ratio | -4.67 | 0.76 | -717.44 |
| research and development expenses | 117706000 | 117841000 | -0.11 |
| operating expenses | 159787000 | 160630000 | -0.52 |
| interest income | 9812000 | 3575000 | 174.46 |
| interest expense | 1373000 | 2216000 | -38.04 |
| ebitda | -122103000 | -124283000 | 1.75 |
| ebitdaratio | -5.88 | -4.05 | -45.23 |
| operating income | -139031000 | -129534000 | -7.33 |
| operating income ratio | -6.7 | -4.17 | -60.80 |
| net income | -132493000 | -126499000 | -4.74 |
| net income ratio | -6.38 | -4.07 | -56.92 |
| eps | -2.67 | -2.59 | -3.09 |
Revenue Growth: revenue decreased to 21 million in 2023 from 31 million in 2022 representing a change of -33.25%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to -97 million in 2023 from 24 million in 2022 representing a change of -512.13%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 118 million in 2023 from 118 million in 2022 representing a change of -0.11%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -122 million in 2023 from -124 million in 2022 representing a change of 1.75%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Earnings per Share (EPS): EPS increased to -2.67 in 2023 from -2.67 in 2022 representing a change of -3.09%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Operating Expenses: Operating Expenses decreased to 160 million in 2023 from 161 million in 2022 representing a change of -0.52%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Operating Income: Operating income increased to -139 million in 2023 from -130 million in 2022 representing a change of -7.33%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -132 million in 2023 from -126 million in 2022 representing a change of -4.74%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001662579 | |||
| revenue | 15362000 | 12006000 | 27.95 |
| gross profit | 13306000 | 9961000 | 33.58 |
| gross profit ratio | 0.87 | 0.83 | 4.40 |
| research and development expenses | 31838000 | 23753000 | 34.04 |
| operating expenses | 43606000 | 33448000 | 30.37 |
| interest income | 3578000 | 3726000 | -3.97 |
| interest expense | 0 | 0 | NaN |
| ebitda | -22610000 | -15671000 | -44.28 |
| ebitdaratio | -1.47 | -1.79 | 17.59 |
| operating income | -28244000 | -21442000 | -31.72 |
| operating income ratio | -1.84 | -1.79 | -2.95 |
| net income | -24666000 | -17716000 | -39.23 |
| net income ratio | -1.61 | -1.48 | -8.81 |
| eps | -0.35 | -0.26 | -34.62 |
Revenue Growth: revenue increased to 15 million in 2024Q2 from 12 million in 2024Q1 representing a change of 27.95%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 13 million in 2024Q2 from 10 million in 2024Q1 representing a change of 33.58%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 32 million in 2024Q2 from 24 million in 2024Q1 representing a change of 34.04%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -23 million in 2024Q2 from -16 million in 2024Q1 representing a change of -44.28%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -28 million in 2024Q2 from -21 million in 2024Q1 representing a change of -31.72%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -25 million in 2024Q2 from -18 million in 2024Q1 representing a change of -39.23%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Operating Expenses: Operating Expenses increased to 44 million in 2024Q2 from 33 million in 2024Q1 representing a change of 30.37%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -0.35 in 2024Q2 from -0.35 in 2024Q1 representing a change of -34.62%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001662579 | |||
| total assets | 376451000 | 430840000 | -12.62 |
| total liabilities | 130336999 | 141606000 | -7.96 |
| total equity | 246114000 | 289234000 | -14.91 |
| cash and cash equivalents | 126590000 | 29754000 | 325.46 |
| short term investments | 127091000 | 246399000 | -48.42 |
| long term investments | 31451000 | 60962000 | -48.41 |
| total current assets | 271189000 | 287557000 | -5.69 |
| total non current assets | 105262000 | 143283000 | -26.54 |
| total current liabilities | 42766000 | 44546000 | -4.00 |
| total non current liabilities | 87571000 | 97060000 | -9.78 |
| common stock | 6000 | 5000 | 20.00 |
| retained earnings | -528383000 | -395890000 | -33.47 |
| total debt | 70976000 | 87152000 | -18.56 |
Total Assets: Total Assets decreased to 376 million in 2023 from 431 million in 2022 representing a change of -12.62%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 246 million in 2023 from 289 million in 2022 representing a change of -14.91%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 127 million in 2023 from 246 million in 2022 representing a change of -48.42%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 271 million in 2023 from 288 million in 2022 representing a change of -5.69%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -528 million in 2023 from -396 million in 2022 representing a change of -33.47%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 130 million in 2023 from 142 million in 2022 representing a change of -7.96%. This indicates a decrease in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 127 million in 2023 from 30 million in 2022 representing a change of 325.46%. This indicates an increase in available liquid assets.
Total Current Liabilities: Total Current Liabilities decreased to 43 million in 2023 from 45 million in 2022 representing a change of -4.0%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 20.0%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 71 million in 2023 from 87 million in 2022 representing a change of -18.56%. This indicates a reduction in overall debt burden.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001662579 | |||
| total assets | 376060000 | 381093000 | -1.32 |
| total liabilities | 133404000 | 134035000 | -0.47 |
| total equity | 242656000 | 247058000 | -1.78 |
| cash and cash equivalents | 59649000 | 73114000 | -18.42 |
| short term investments | 195992000 | 190984000 | 2.62 |
| long term investments | 0 | 35080000 | -100.00 |
| total current assets | 273228000 | 276044000 | -1.02 |
| total non current assets | 102832000 | 105049000 | -2.11 |
| total current liabilities | 43293000 | 54201000 | -20.13 |
| total non current liabilities | 90111000 | 79834000 | 12.87 |
| common stock | 7000 | 7000 | 0.00 |
| retained earnings | -599126000 | -574460000 | -4.29 |
| total debt | 67095000 | 68417000 | -1.93 |
Total Assets: Total Assets decreased to 376 million in 2024Q2 from 381 million in 2024Q1 representing a change of -1.32%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 243 million in 2024Q2 from 247 million in 2024Q1 representing a change of -1.78%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 60 million in 2024Q2 from 73 million in 2024Q1 representing a change of -18.42%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 273 million in 2024Q2 from 276 million in 2024Q1 representing a change of -1.02%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -599 million in 2024Q2 from -574 million in 2024Q1 representing a change of -4.29%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 133 million in 2024Q2 from 134 million in 2024Q1 representing a change of -0.47%. This indicates a decrease in overall liabilities.
Short Term Investments: Short Term Investments increased to 196 million in 2024Q2 from 191 million in 2024Q1 representing a change of 2.62%. This indicates an increase in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities decreased to 43 million in 2024Q2 from 54 million in 2024Q1 representing a change of -20.13%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 67 million in 2024Q2 from 68 million in 2024Q1 representing a change of -1.93%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001662579 | |||
| net change in cash | 97000000 | -46370000 | 309.19 |
| operating cash flow | -106838000 | -105939000 | -0.85 |
| free cash flow | -108546000 | -111435000 | 2.59 |
| capital expenditure | -1708000 | -5496000 | 68.92 |
| depreciation and amortization | 1880000 | 1676000 | 12.17 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 27235000 | 30016000 | -9.27 |
| accounts payables | 273000 | -3333000 | 108.19 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | -63918000 | 100.00 |
| investments in property plant and equipment | -1708000 | -5496000 | 68.92 |
| net cash used for investing activites | 158349000 | 58422000 | 171.04 |
| debt repayment | -12500000 | 0 | NaN |
| common stock issued | 57673000 | 777000 | 7,322.52 |
| common stock repurchased | -110000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 45489000 | 1147000 | 3,865.91 |
| cash at end of period | 130033000 | 33033000 | 293.65 |
| accounts receivables | -10327000 | 4244000 | -343.33 |
| cash at beginning of period | 33033000 | 79403000 | -58.40 |
Net Change in Cash: Net Change in Cash increased to 97 million in 2023 from -46 million in 2022 representing a change of 309.19%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Free Cash Flow: Free Cash Flow increased to -109 million in 2023 from -111 million in 2022 representing a change of 2.59%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 27 million in 2023 from 30 million in 2022 representing a change of -9.27%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2023 from 3 million in 2022 representing a change of 108.19%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -10 million in 2023 from 4 million in 2022 representing a change of -343.33%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to -107 million in 2023 from -106 million in 2022 representing a change of -0.85%. This indicates that the company generated less cash from its core business operations.
Capital Expenditure: Capital Expenditure increased to -2 million in 2023 from -5 million in 2022 representing a change of 68.92%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001662579 | |||
| operating cash flow | -24133000 | -4974000 | -385.18 |
| free cash flow | -24120000 | -5171000 | -366.45 |
| capital expenditure | 13000 | -197000 | 106.60 |
| depreciation and amortization | -2734000 | 2045000 | -233.69 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 8831000 | 6381000 | 38.40 |
| accounts receivables | -9174000 | 12431000 | -173.80 |
| accounts payables | 590000 | -715000 | 182.52 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 13000 | -197000 | 106.60 |
| net cash used for investing activites | 162000 | -11706000 | 101.38 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 10294000 | 135000 | 7,525.19 |
| common stock repurchased | -85000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 10506000 | 135000 | 7,682.22 |
| net change in cash | -10022000 | -16545000 | 39.43 |
| cash at end of period | 63092000 | 73114000 | -13.71 |
| cash at beginning of period | 73114000 | 89659000 | -18.45 |
Net Change in Cash: Net Change in Cash increased to -10 million in 2024Q2 from -17 million in 2024Q1 representing a change of 39.43%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Accounts Payables: The absolute value of Accounts Payables decreased to 1 million in 2024Q2 from 1 million in 2024Q1 representing a change of 182.52%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -9 million in 2024Q2 from 12 million in 2024Q1 representing a change of -173.8%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to -24 million in 2024Q2 from -5 million in 2024Q1 representing a change of -385.18%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -24 million in 2024Q2 from -5 million in 2024Q1 representing a change of -366.45%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of 106.6%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 9 million in 2024Q2 from 6 million in 2024Q1 representing a change of 38.4%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.42 | 0.64 | -34.30 |
| net income per share | -2.67 | -2.59 | -3.10 |
| operating cash flow per share | -2.15 | -2.17 | 0.73 |
| free cash flow per share | -2.19 | -2.28 | 4.12 |
| cash per share | 5.11 | 5.65 | -9.58 |
| book value per share | 4.96 | 5.92 | -16.24 |
| tangible book value per share | 4.96 | 5.92 | -16.24 |
| shareholders equity per share | 4.96 | 5.92 | -16.24 |
| interest debt per share | 1.46 | 0.38 | 287.07 |
| market cap | 280468853.25 | 288283823.5 | -2.71 |
| enterprise value | 224854853.25 | 345681823.5 | -34.95 |
| pe ratio | -2.12 | -2.28 | 7.11 |
| price to sales ratio | 13.51 | 9.27 | 45.76 |
| pocfratio | -2.63 | -2.72 | 3.53 |
| pfcf ratio | -2.58 | -2.59 | 0.12 |
| pb ratio | 1.14 | 1.0 | 14.33 |
| ptb ratio | 1.14 | 1.0 | 14.33 |
| ev to sales | 10.83 | 11.12 | -2.55 |
| enterprise value over ebitda | -1.84 | -2.78 | 33.79 |
| ev to operating cash flow | -2.1 | -3.26 | 35.50 |
| ev to free cash flow | -2.07 | -3.1 | 33.22 |
| earnings yield | -0.47 | -0.44 | -7.66 |
| free cash flow yield | -0.39 | -0.39 | -0.12 |
| debt to equity | 0.29 | 0.06 | 415.46 |
| debt to assets | 0.19 | 0.04 | 401.98 |
| net debt to ebitda | 0.46 | -0.46 | 198.62 |
| current ratio | 6.34 | 6.46 | -1.77 |
| interest coverage | -101.26 | -58.45 | -73.23 |
| income quality | 0.81 | 0.83 | -2.44 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 2.03 | 1.38 | 47.34 |
| research and ddevelopement to revenue | 5.67 | 3.79 | 49.65 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.02 | -0.05 | 69.18 |
| capex to revenue | 0.08 | 0.18 | -53.44 |
| capex to depreciation | 0.91 | 3.28 | -72.30 |
| stock based compensation to revenue | 1.31 | 0.97 | 35.94 |
| graham number | 17.26 | 18.57 | -7.08 |
| roic | -0.44 | -0.42 | -5.77 |
| return on tangible assets | -0.35 | -0.29 | -19.87 |
| graham net net | 2.66 | 2.15 | 23.72 |
| working capital | 228423000 | 243011000 | -6.00 |
| tangible asset value | 246114001 | 289234000 | -14.91 |
| net current asset value | 140852001 | 145951000 | -3.49 |
| invested capital | 299511000 | 320527000 | -6.56 |
| average receivables | 6636000 | 3594500 | 84.62 |
| average payables | 1309000 | 2839000 | -53.89 |
| average inventory | -30481000 | -30481000 | 0.00 |
| days sales outstanding | 207.49 | 17.29 | 1,100.06 |
| days payables outstanding | 4.48 | 56.49 | -92.06 |
| days of inventory on hand | 0 | -2938.61 | 100.00 |
| receivables turnover | 1.76 | 21.11 | -91.67 |
| payables turnover | 81.4 | 6.46 | 1,159.93 |
| inventory turnover | 0 | -0.12 | 100.00 |
| roe | -0.54 | -0.44 | -23.09 |
| capex per share | 0.03 | 0.11 | -69.41 |
ROE: Return on Equity (ROE) decreased to -0.54 on 2023-12-31 from -0.44 on 2022-12-31, representing a change of -23.09%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 6.34 on 2023-12-31 from 6.46 on 2022-12-31, representing a change of -1.77%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -2.12 on 2023-12-31 from -2.28 on 2022-12-31, representing a change of 7.11%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.29 on 2023-12-31 from 0.06 on 2022-12-31, representing a change of 415.46%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q2 | 2024-06-30 Q1 | Q/Q change % | |
|---|---|---|---|
| CCCC | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.22 | 0.17 | 26.45 |
| net income per share | -0.35 | -0.26 | -37.60 |
| operating cash flow per share | -0.35 | -0.07 | -379.49 |
| free cash flow per share | -0.35 | -0.08 | -360.97 |
| cash per share | 3.67 | 3.84 | -4.34 |
| book value per share | 3.49 | 3.59 | -2.93 |
| tangible book value per share | 3.49 | 3.59 | -2.93 |
| shareholders equity per share | 3.49 | 3.59 | -2.93 |
| interest debt per share | 0.08 | 0.99 | -91.86 |
| market cap | 396874983 | 333729756.15 | 18.92 |
| enterprise value | 404320983 | 329032756.15 | 22.88 |
| pe ratio | -4.02 | -4.71 | 14.59 |
| price to sales ratio | 25.83 | 27.8 | -7.06 |
| pocfratio | -16.45 | -67.09 | 75.49 |
| pfcf ratio | -16.45 | -64.54 | 74.50 |
| pb ratio | 1.64 | 1.35 | 21.08 |
| ptb ratio | 1.64 | 1.35 | 21.08 |
| ev to sales | 26.32 | 27.41 | -3.96 |
| enterprise value over ebitda | -17.88 | -21.0 | 14.83 |
| ev to operating cash flow | -16.75 | -66.15 | 74.67 |
| ev to free cash flow | -16.76 | -63.63 | 73.66 |
| earnings yield | -0.06 | -0.05 | -17.08 |
| free cash flow yield | -0.06 | -0.02 | -292.23 |
| debt to equity | 0.02 | 0.28 | -91.62 |
| debt to assets | 0.01 | 0.18 | -91.66 |
| net debt to ebitda | -0.33 | 0.3 | -209.87 |
| current ratio | 6.31 | 5.09 | 23.92 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.98 | 0.28 | 248.48 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.77 | 0.81 | -5.14 |
| research and ddevelopement to revenue | 2.07 | 1.98 | 4.76 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.04 | 98.64 |
| capex to revenue | 0.0 | 0.02 | -94.84 |
| capex to depreciation | -0.0 | 0.1 | -104.94 |
| stock based compensation to revenue | 0.57 | 0.53 | 8.16 |
| graham number | 5.27 | 4.56 | 15.57 |
| roic | -0.11 | -0.06 | -89.21 |
| return on tangible assets | -0.07 | -0.05 | -41.09 |
| graham net net | 1.87 | 1.9 | -1.89 |
| working capital | 229935000 | 221843000 | 3.65 |
| tangible asset value | 242656000 | 247058000 | -1.78 |
| net current asset value | 139824000 | 142009000 | -1.54 |
| invested capital | 295308000 | 289195000 | 2.11 |
| average receivables | 5754000 | 7383000 | -22.06 |
| average payables | 1208500 | 1271500 | -4.95 |
| average inventory | 0.5 | 0.5 | 0.00 |
| days sales outstanding | 60.58 | 8.75 | 592.54 |
| days payables outstanding | 65.84 | 40.18 | 63.85 |
| days of inventory on hand | 0 | 0.0 | -100.00 |
| receivables turnover | 1.49 | 10.29 | -85.56 |
| payables turnover | 1.37 | 2.24 | -38.97 |
| inventory turnover | 0 | 2045000 | -100.00 |
| roe | -0.1 | -0.07 | -41.76 |
| capex per share | 0.0 | 0.0 | -93.48 |
ROE: Return on Equity (ROE) decreased to -0.10 on 2024-09-30 Q2 from -0.07 on 2024-06-30 Q1, representing a change of -41.76%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 6.31 on 2024-09-30 Q2 from 5.09 on 2024-06-30 Q1, representing a change of 23.92%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -4.02 on 2024-09-30 Q2 from -4.71 on 2024-06-30 Q1, representing a change of 14.59%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.02 on 2024-09-30 Q2 from 0.28 on 2024-06-30 Q1, representing a change of -91.62%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is -1.48 which is lower than current price 4.72, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2024-10-31 09:20:23
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.55 per share a year ago.
Sentiment: Positive
Publish Date: 2024-10-28 16:01:00
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 345,600 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on October 28, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
Sentiment: Neutral
Publish Date: 2024-10-15 16:01:00
Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios
Sentiment: Negative
Publish Date: 2024-10-09 07:00:00
WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its participation in the 7th Annual Targeted Protein Degradation & Induced Proximity Summit, to be held October 28-31, 2024, in Boston, MA. Four members of the company's leadership team will deliver oral presentations or participate on panels to demonstrate the company's expertise in designing and developing highly catalytic orally bioavailable degraders that have the potential to transform patients' lives.
Sentiment: Positive
Publish Date: 2024-09-30 16:01:00
WATERTOWN, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on September 30, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
Sentiment: Negative
Publish Date: 2024-09-13 10:00:00
CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein Early Evidence of CFT1946 Monotherapy Anti-Tumor Activity in Patients Who Have Progressed on or After BRAF Inhibitor Therapies; Majority of Patients Demonstrated Tumor Reduction Across V600 Mutation Types CFT1946 Global Phase 1 Trial Continues to Enroll; Monotherapy and Combination Expansion Cohorts Advancing With Additional Data Expected in 2025 C4T To Host Webcast Today at 12:00 pm ET; Webcast Link Available Here WATERTOWN, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced initial clinical data from the ongoing clinical trial of CFT1946, an orally bioavailable small molecule degrader of BRAF V600 mutations in solid tumors.
Sentiment: Positive
Publish Date: 2024-09-08 18:05:00
Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity Investor Webcast to be Held Friday, September 13, 2024 at 12:00 pm ET WATERTOWN, Mass., Sept. 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the abstract sharing clinical data from its ongoing Phase 1 clinical trial of CFT1946, a novel BiDAC™ degrader, in mutant BRAF V600 solid tumors, was released in conjunction with the ESMO Congress 2024 scheduled for September 13 – 17, 2024 in Barcelona, Spain.
Sentiment: Negative
Publish Date: 2024-09-03 07:00:00
WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service.
Sentiment: Negative
Publish Date: 2024-08-29 07:00:00
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor conferences.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
